Nearly a quarter of patients with difficult-to-control type 2 diabetes have hypercortisolism, with even higher prevalence ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic ...

Clinicians who are unaware of the pseudocondition may mistake elevated cortisol results for signs of true Cushing syndrome ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Corcept Therapeutics Incorporated’s CORT share price has surged by 7.18%, which has investors questioning if this is right time to sell.

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going ...